Ready to Use Biosimilar Cell Lines
You do not want to wait until you have your desired biosimilar cell line in hands? UGA Biopharma promote a broad spectrum of Ready to Use Biosimilar Cell Lines including documentation which are ready to out-license to a collaboration partner. In addition UGA Biopharma can accelerate your way to success by providing an optimized bioprocess, downstream process and analytical data and methods.
Ready To Use Biosimilar Cell Lines read more
Adalimumab Biosimilar (limited use only*)
Full package ready for sales now:
Research Cell Bank (RCB) including safety testing
Optimized fermentation process (USP)
Optimized downstream purification process (DSP) and analytics
Including proof of activity of the expressed protein
If you have any further question about the
licensing conditions of the cell line, please do not hesitate to contact us
via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for
experimental use relating to the subject-matter of the patented invention or
for studies and trials necessary to obtain a marketing authorization for
medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent
Act, but not in any larger quantities, nor for any other purposes.
Aflibercept Biosimilar (limited use only*)
Aflibercept is a recombinant fusion protein with complex
post-translational modifications. Therefore deep understanding of biosimilar
development is required to develop a biosimilar like Aflibercept.
If you have any further question about the
licensing conditions of the cell line, please do not hesitate to contact us
via: info@ugabiopharma.com
Please you consider the disclaimer on this website.
Alirocumab Biosimilar (limited use only*)
If you have any further question about the
licensing conditions of the cell line, please do not hesitate to contact us
via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for
experimental use relating to the subject-matter of the patented invention or
for studies and trials necessary to obtain a marketing authorization for
medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent
Act, but not in any larger quantities, nor for any other purposes.
Anakinra Biosimilar (limited use only*)
If you have any further question about the
licensing conditions of the cell line, please do not hesitate to contact us
via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for
experimental use relating to the subject-matter of the patented invention or
for studies and trials necessary to obtain a marketing authorization for
medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent
Act, but not in any larger quantities, nor for any other purposes.
Bevacizumab Biosimilar (limited use only*)
Remarkable Bevacizumab clone stability for at least 10 weeks of cultivation.
If you have any further question about the
licensing conditions of the cell line, please do not hesitate to contact us
via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for
experimental use relating to the subject-matter of the patented invention or
for studies and trials necessary to obtain a marketing authorization for
medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent
Act, but not in any larger quantities, nor for any other purposes.
Certolizumab Biosimilar (limited use only*)
If you have any further question about the
licensing conditions of the cell line, please do not hesitate to contact us
via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for
experimental use relating to the subject-matter of the patented invention or
for studies and trials necessary to obtain a marketing authorization for
medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent
Act, but not in any larger quantities, nor for any other purposes.
Darbepoetin alfa Biosimilar (limited use only*)
Biosimilary of Darbepoetin alfa expressing cell line could be improved. Please consider the isolectical focusing (IEF) gel of Darbepoetin alfa biosimilars and the originator.
If you have any further question about the
licensing conditions of the cell line, please do not hesitate to contact us
via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for
experimental use relating to the subject-matter of the patented invention or
for studies and trials necessary to obtain a marketing authorization for
medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent
Act, but not in any larger quantities, nor for any other purposes.
Dulaglutide Biosimilar (limited use only*)
If you have any further question about the
licensing conditions of the cell line, please do not hesitate to contact us
via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.
Dupilumab Biosimilar (limited use only*)
An
outstanding product concentration higher than 7 g/L could be reached during the
Dupilumab development project! The first CHOice® Medium works very
well for Dupilumab clones.
If you have any further question about the
licensing conditions of the cell line, please do not hesitate to contact us
via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for
experimental use relating to the subject-matter of the patented invention or
for studies and trials necessary to obtain a marketing authorization for
medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent
Act, but not in any larger quantities, nor for any other purposes.
Erenumab Biosimilar (limited use only*)
If you have any further question about the
licensing conditions of the cell line, please do not hesitate to contact us
via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.
Ipilimumab Biosimilar (limited use only*)
Typical
charge profil of ther reference medical product of Ipilimumab.
If you have any further question about the
licensing conditions of the cell line, please do not hesitate to contact us
via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for
experimental use relating to the subject-matter of the patented invention or
for studies and trials necessary to obtain a marketing authorization for
medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent
Act, but not in any larger quantities, nor for any other purposes.
Mepolizumab Biosimilar (limited use only*)
If you have any further question about the
licensing conditions of the cell line, please do not hesitate to contact us
via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for
experimental use relating to the subject-matter of the patented invention or
for studies and trials necessary to obtain a marketing authorization for
medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent
Act, but not in any larger quantities, nor for any other purposes.
Natalizumab Biosimilar (limited use only*)
The
primary structure of a biosimilar has to be identical to the originator
molecule. The result of the peptide mapping of the Natalizumab biosimilar is
depicted here.
If you have any further question about the
licensing conditions of the cell line, please do not hesitate to contact us
via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for
experimental use relating to the subject-matter of the patented invention or
for studies and trials necessary to obtain a marketing authorization for
medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent
Act, but not in any larger quantities, nor for any other purposes.
Nivolumab Biosimilar (limited use only*)
A product
concentration over 3 g/L has been obtained during a Nivolumab consistency run
in stirred bioreactors.
If you have any further question about the
licensing conditions of the cell line, please do not hesitate to contact us
via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for
experimental use relating to the subject-matter of the patented invention or
for studies and trials necessary to obtain a marketing authorization for
medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent
Act, but not in any larger quantities, nor for any other purposes.
Omalizumab Biosimilar (limited use only*)
A product
concentration of 3 g/L has been obtained during the Omalizumab biosimilar
development project.
If you have any further question about the
licensing conditions of the cell line, please do not hesitate to contact us
via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for
experimental use relating to the subject-matter of the patented invention or
for studies and trials necessary to obtain a marketing authorization for
medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent
Act, but not in any larger quantities, nor for any other purposes.
Panitumumab Biosimilar (limited use only*)
If you have any further question about the
licensing conditions of the cell line, please do not hesitate to contact us
via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for
experimental use relating to the subject-matter of the patented invention or
for studies and trials necessary to obtain a marketing authorization for
medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent
Act, but not in any larger quantities, nor for any other purposes.
Pembrolizumab Biosimilar (limited use only*)
Pembrolizumab
(IgG4) biosimilar development project has been finalized in a very short time
line – according to the High Speed Workflow of UGA Biopharma!
If you have any further question about the
licensing conditions of the cell line, please do not hesitate to contact us
via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for
experimental use relating to the subject-matter of the patented invention or
for studies and trials necessary to obtain a marketing authorization for
medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent
Act, but not in any larger quantities, nor for any other purposes.
Pertuzumab Biosimilar (limited use only*)
Outstanding productivity higher than 5 g/L reached during the pertuzumab development project!
If you have any further question about the
licensing conditions of the cell line, please do not hesitate to contact us
via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for
experimental use relating to the subject-matter of the patented invention or
for studies and trials necessary to obtain a marketing authorization for
medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent
Act, but not in any larger quantities, nor for any other purposes.
Secukinumab Biosimilar (limited use only*)
If you have any further question about the
licensing conditions of the cell line, please do not hesitate to contact us
via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for
experimental use relating to the subject-matter of the patented invention or
for studies and trials necessary to obtain a marketing authorization for
medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent
Act, but not in any larger quantities, nor for any other purposes.
Under Development
Efmoroctocog alfa Biosimilar (limited use only*)
This biosimilar project is under
development at UGA Biopharma GmbH.
If you have any further question about the
licensing conditions of the cell line, please do not hesitate to contact us
via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for
experimental use relating to the subject-matter of the patented invention or
for studies and trials necessary to obtain a marketing authorization for
medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent
Act, but not in any larger quantities, nor for any other purposes.
Elosulfase Biosimilar (limited use only*)
This biosimilar project is under
development at UGA Biopharma GmbH.
If you have any further question about the
licensing conditions of the cell line, please do not hesitate to contact us
via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for
experimental use relating to the subject-matter of the patented invention or
for studies and trials necessary to obtain a marketing authorization for
medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent
Act, but not in any larger quantities, nor for any other purposes.
Galsulfase Biosimilar (limited use only*)
This biosimilar project is under
development at UGA Biopharma GmbH.
If you have any further question about the
licensing conditions of the cell line, please do not hesitate to contact us
via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for
experimental use relating to the subject-matter of the patented invention or
for studies and trials necessary to obtain a marketing authorization for
medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent
Act, but not in any larger quantities, nor for any other purposes.
Idursulfase Biosimilar (limited use only*)
This biosimilar project is under
development at UGA Biopharma GmbH.
If you have any further question about the
licensing conditions of the cell line, please do not hesitate to contact us
via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for
experimental use relating to the subject-matter of the patented invention or
for studies and trials necessary to obtain a marketing authorization for
medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent
Act, but not in any larger quantities, nor for any other purposes.
Trastuzumab Biosimilar (limited use only*)
This biosimilar project is under
development at UGA Biopharma GmbH.
If you have any further question about the
licensing conditions of the cell line, please do not hesitate to contact us
via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for
experimental use relating to the subject-matter of the patented invention or
for studies and trials necessary to obtain a marketing authorization for
medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent
Act, but not in any larger quantities, nor for any other purposes.
Disclaimer
*Limited use only: Until the expiration of the patent and potential supplementary protection certificates related to the reference medical product the client must not (i) produce, offer or put on the market the respective medical product or possess the product for such purposes, or (ii) use the cell lines or products offered by UGA Biopharma except for experimental use or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act.
Back to products and services
Contact
UGA Biopharma GmbHNeuendorfstraße 20a
16761 Hennigsdorf
Germany
E-mail: info@ugabiopharma.com
Phone: +49(0)3302 / 2024900